This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...
Final analysis from the phase 2 OVATION 2 trial (NCT03393884) has demonstrated a continued and growing overall survival (OS) ...
Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...
Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...
Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
Theriva Biologics has received FDA agreement on the core design elements of a pivotal phase 3 trial evaluating zabilugene ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results